Add like
Add dislike
Add to saved papers

Cu 2 O-promoted degradation of sulfamethoxazole by α-Fe 2 O 3 -catalyzed peroxymonosulfate under circumneutral conditions: synergistic effect, Cu/Fe ratios, and mechanisms.

To promote the application of iron oxides in sulfate radical-based advanced oxidation processes, a convenient approach using Cu2 O as a catalyst additive was proposed. Composite catalysts based on α-Fe2 O3 (CTX%Cu2 O, X = 1, 2.5, 5, and 10) were prepared for peroxymonosulfate (PMS) activation, and sulfamethoxazole was used as a model pollutant to probe the catalytic reactivity. The results show that a synergistic catalytic effect exists between Cu2 O and α-Fe2 O3 , which was explained by the promoted reduction of Fe(III) by Cu(I). Iron K-edge X-ray absorption spectroscopy investigations indicated that the promoted reduction probably occurred with PMS acting as a ligand that bridges the redox centers of Cu(I) and Fe(III). The weight ratio between Cu2 O and α-Fe2 O3 influenced the degradation of sulfamethoxazole, and the optimal ratio depended on the dosage of PMS and catalysts. With 40 mg L-1 PMS and 0.6 g L-1 catalyst, a pseudo-first-order constant of ∼0.019 min-1 was achieved for CT2.5%Cu2 O, whereas only 0.004 min-1 was realized for α-Fe2 O3 . Nearly complete degradation of the sulfamethoxazole was achieved within 180 min under the conditions of 40 mg L-1 PMS, 0.4 g L-1 CT2.5%Cu2 O, and pH 6.8. In contrast, less than 20% degradation was realized with α-Fe2 O3 under similar conditions. The CT2.5%Cu2 O catalyst had the best stoichiometric efficiency of PMS (0.317), which was 4.5 and 5.8 times higher than those of Cu2 O (0.070) and α-Fe2 O3 (0.054), respectively. On the basis of the products identified, the cleavage of the S-N bond was proposed as a major pathway for the degradation of sulfamethoxazole.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app